ASP Isotopes (ASPI, Financial) has announced plans to establish a secondary listing for its common stock on the Main Board of the Johannesburg Stock Exchange (JSE). The company will maintain its current listing on the Nasdaq Capital Market. This move is rooted in ASPI’s strong connections to South Africa, where its technological advancements have been pioneered by a skilled local team over the past four years.
Currently, ASPI operates three plants in Pretoria, focusing on the commercial production of isotopes such as Carbon-14, Silicon-28, and Ytterbium-176. These elements are critical for applications in the pharmaceutical, medical, quantum computing, and semiconductor industries.
The decision to list on the JSE is anticipated to be advantageous for ASP Isotopes and its stakeholders. It aims to increase liquidity for shareholders, broaden the company’s shareholder base, and support future growth by leveraging another significant capital market. The listing on the JSE is expected to proceed later this year, subject to receiving the necessary regulatory approvals in South Africa.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for ASP Isotopes Inc (ASPI, Financial) is $6.50 with a high estimate of $8.50 and a low estimate of $4.50. The average target implies an upside of 14.84% from the current price of $5.66. More detailed estimate data can be found on the ASP Isotopes Inc (ASPI) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, ASP Isotopes Inc's (ASPI, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
